AbbVie Drops $600M on China Asset, Faces House Scrutiny, Takes ADARx Stake
ABBV sits 39% above its 52-week low of $190.75.
Summary
AbbVie paid at least $600 million upfront for rights to a single Chinese asset, a major cash outlay that signals aggressive expansion in China. Simultaneously, a House committee is requesting trial files and data protection details from AbbVie's China clinical sites, adding regulatory and political risk to that strategy. The company also bought a 4.9% stake in ADARx via a private placement at $16 per share (~$78.5 million) alongside ADARx's planned IPO, and partnered with Iambic on a deal with upfront, milestone, and royalty payments. These moves follow AbbVie's recent $10 billion bond issuance to fund its Apogee acquisition, showing continued heavy investment in pipeline and partnerships. The House inquiry could escalate into a broader compliance issue, while the China licensing deal's size relative to AbbVie's $467 billion market cap is modest but strategically notable.
At the time of this announcement, ABBV was trading at $265.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $467.4B. The 52-week trading range was $190.75 to $267.47. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.